Bessemer Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Bessemer Group’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-20	Closed	–	–	2520
2024 Q3	$0	Buy	+20	New	+$332	﹤0.01%	2631

Other funds holding FDMT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bessemer Group's FDMT Position: Q4 2024 in Review

Bessemer Group sold out of 4D Molecular Therapeutics (FDMT) in Q4 2024, closing a stake of 20 shares.

Bessemer Group first reported a position in FDMT in Q3 2024 and held it in 1 quarter. The position peaked at $0 in Q3 2024. 145 funds tracked by Wall St. Rank hold FDMT as of Q4 2024.

Bessemer Group reported no remaining 4D Molecular Therapeutics position as of Q4 2024 after selling out during the quarter.
Bessemer Group sold 20 4D Molecular Therapeutics shares in Q4 2024.
Bessemer Group first reported a position in 4D Molecular Therapeutics in Q3 2024 and held it in 1 quarter.
Bessemer Group's 4D Molecular Therapeutics position peaked at $0 in Q3 2024.
145 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2024.

Based on Bessemer Group's 13F filing for Q4 2024, filed 13 Feb 2025.